Roche has revealed the data behind a positive phase 3 trial for its oral BTK inhibitor fenebrutinib in primary progressive multiple sclerosis (PPMS), revealing that it was at least as effective as its ...
Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS). The ...
Data analytics in the social sciences (DASS) combines coursework and learning opportunities from our social sciences departments at UB: sociology, linguistics, psychology, geography, anthropology, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results